

CITATION REPORT

List of articles citing

The bile acid membrane receptor TGR5: a valuable metabolic target

DOI: 10.1159/000324126

Digestive Diseases, 2011, 29, 37-44.

Source: <https://exaly.com/paper-pdf/52015930/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
114	Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. 2011 , 11, 2150-8		37
113	Bile acid sequestrants: more than simple resins. 2012 , 23, 43-55		60
112	Cholecystectomy and NAFLD: does gallbladder removal have metabolic consequences?. 2013 , 108, 959-61		26
111	Transport and biological activities of bile acids. 2013 , 45, 1389-98		67
110	The bile acid receptor TGR5 does not interact with β arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. 2013 , 288, 22942-60		69
109	Pleiotropic roles of bile acids in metabolism. 2013 , 17, 657-69		586
108	The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. 2013 , 33, 213-23		53
107	An association between post-meal bile acid response and bone resorption in normal subjects. 2013 , 50, 558-63		7
106	Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. 2013 , 304, G371-80		109
105	Association of cholecystectomy with metabolic syndrome in a Chinese population. 2014 , 9, e88189		24
104	Mechanisms of bile formation and cholestasis. 24-31		1
103	Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes. 2014 , 9, e115175		83
102	Gut microbiota composition and its effects on obesity and insulin resistance. 2014 , 17, 312-8		39
101	Potential of pharmacological modulation of level and activity of incretins in diabetes mellitus type 2. 2014 , 8, 293-301		
100	TGR5 reduces macrophage migration through mTOR-induced C/EBP β differential translation. 2014 , 124, 5424-36		121
99	Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. 2014 , 140, 133-44		8
98	Bile metabolism and lithogenesis. 2014 , 94, 361-75		23

97	Cross-talk between liver and intestine in control of cholesterol and energy homeostasis. 2014 , 37, 77-88	18
96	Peripheral targets in obesity treatment: a comprehensive update. 2014 , 15, 487-503	27
95	4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists. 2014 , 82, 1-15	24
94	Beyond intestinal soap--bile acids in metabolic control. 2014 , 10, 488-98	280
93	Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. 2014 , 60, 824-31	353
92	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. 2014 , 383, 1068-83	915
91	Vitamin D and energy homeostasis: of mice and men. 2014 , 10, 79-87	83
90	Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy. 2014 , 57, 3263-82	31
89	Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. 2014 , 70, 667-74	15
88	The bile acid TGR5 membrane receptor: from basic research to clinical application. 2014 , 46, 302-12	266
87	Targeting fatty acid metabolism to improve glucose metabolism. 2015 , 16, 715-57	92
86	Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. 2015 , 21, 6287-95	36
85	Specific inhibition of bile acid transport alters plasma lipids and GLP-1. 2015 , 15, 75	37
84	Gut MicrobiotaImmune System Crosstalk. 2015 , 127-137	2
83	The brain and brown fat. 2015 , 47, 150-68	104
82	Membrane bile acid receptor TGR5 predicts good prognosis in ampullary adenocarcinoma patients with hyperbilirubinemia. 2016 , 36, 1997-2008	14
81	Retention data of bile acids and their oxo derivatives in characterization of pharmacokinetic properties and in silico ADME modeling. 2016 , 92, 194-202	12
80	Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?. 2016 , 280, 476-486	36

79	Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect. 2016 , 6, 28676	29
78	The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. 2016 , 65, 54-63	48
77	Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. 2016 , 310, G81-92	57
76	Single and dual cyclodextrins systems for the enantiomeric and diastereoisomeric separations of structurally related dihydropyridone analogues. 2017 , 38, 1922-1931	9
75	Traveling from the hypothalamus to the adipose tissue: The thermogenic pathway. 2017 , 12, 854-863	59
74	Cellular Injury in Liver Diseases. 2017 ,	0
73	Bile Acid-Induced Liver Injury in Cholestasis. 2017 , 143-172	3
72	The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus. 2017 , 8, 401-409	15
71	Bile Acid Administration Elicits an Intestinal Antimicrobial Program and Reduces the Bacterial Burden in Two Mouse Models of Enteric Infection. 2017 , 85,	27
70	Bile acid metabolism and signaling in liver disease and therapy. 2017 , 1, 3-9	115
69	Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition. 2017 , 41, 198-207	13
68	Interaction of gut microbiota with bile acid metabolism and its influence on disease states. 2017 , 101, 47-64	235
67	Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. 2017 , 12, e0178868	63
66	Regulation of Ca-Sensitive K Channels by Cholesterol and Bile Acids via Distinct Channel Subunits and Sites. 2017 , 80, 53-93	9
65	Cross-Talk Between Bile Acids and Gastro-Intestinal and Thermogenic Hormones: Clues from Bariatric Surgery. 2017 , 16, s68-s82	10
64	The use of antimicrobials as adjuvant therapy for the treatment of obesity and insulin resistance: Effects and associated mechanisms. 2018 , 34, e3014	2
63	Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy: new insights on a complex relationship. 2018 , 34, 90-96	17
62	Cholecystectomy as a risk factor of metabolic syndrome: from epidemiologic clues to biochemical mechanisms. 2018 , 98, 7-14	19

61	Supercritical fluid chromatography versus high performance liquid chromatography for enantiomeric and diastereoisomeric separations on coated polysaccharides-based stationary phases: Application to dihydropyridone derivatives. 2018 , 1549, 39-50	15
60	New Pharmacological Opportunities for Betulinic Acid. 2018 , 84, 8-19	90
59	Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis. 2018 , 4, 1-46	11
58	Bile Acid Metabolism in Liver Pathobiology. 2018 , 18, 71-87	149
57	Pathophysiology of Type 2 Diabetes. 2019 , 101-116	
56	The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. 2019 , 11,	42
55	Gut microbiota and physical frailty through the mediation of sarcopenia. 2019 , 124, 110639	23
54	Gall bladder: The metabolic orchestrator. 2019 , 35, e3140	5
53	Bariatric Endocrinology. 2019 ,	
52	Role of the Gut in the Regulation of Energy Balance and Energy Stores. 2019 , 77-98	1
51	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. 2020 , 9,	40
50	The gut microbiome and frailty. 2020 , 221, 23-43	9
49	A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. 2020 , 55, 102766	39
48	The Response of the Gut Microbiota to Dietary Changes in the First Two Years of Life. 2020 , 11, 334	15
47	Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes. 2020 , 4, 493-503	2
46	Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. 2020 , 16, 1551-1562	41
45	Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. 2021 , 7, 11	7
44	Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid. 2021 , 11, 1045-1069	11

43	Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. 2021 , 16, e0247303	5
42	The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. 2021 , 46, 101175	9
41	Increased Risk of Major Depressive Disorder After Cholecystectomy: A Nationwide Population-Based Cohort Study in Korea. 2021 , 12, e00339	0
40	Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability. 2021 , 60, 971-984	5
39	Bile Acids as Metabolic Inducers of Hepatocyte Proliferation and Liver Regeneration. 1	
38	Colon cancer checks in when bile acids check out: the bile acid-nuclear receptor axis in colon cancer. 2021 , 65, 1015-1024	1
37	Microbiome Metabolites and Thyroid Dysfunction. 2021 , 10,	6
36	TUDCA receptors and their role on pancreatic beta cells. 2021 ,	1
35	Beneficial effects of inorganic nitrate in non-alcoholic fatty liver disease. 2021 , 711, 109032	0
34	Fundamentals of Bicarbonate Secretion in Epithelia. 2016 , 187-263	7
33	Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. 2016 , 22, 7463-77	43
32	Colesevelam-induced hypoglycaemia in a patient with type 1 diabetes mellitus. 2021 , 9, e04830	1
31	Synthesis of new bile acid-fused tetrazoles using the Schmidt reaction. 2021 , 17, 2611-2620	3
30	Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease. 2019 , 29, 17-23	2
29	Taurolithocholic acid but not tauroursodeoxycholic acid rescues phagocytosis activity of bone marrow-derived macrophages under inflammatory stress. 2021 ,	1
28	Fundamentals of Bicarbonate Secretion in Epithelia. 2020 , 461-541	0
27	. 2021 ,	5
26	Aryl hydrocarbon receptor (AhR) activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) dose-dependently shifts the gut microbiome consistent with the progression of steatosis to steatohepatitis with fibrosis.	

25	Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo--Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. 2021 , 22,	0
24	Alternating Dual-Collision Energy Scanning Mass Spectrometry Approach: Discovery of Novel Microbial Bile-Acid Conjugates.. 2022 ,	1
23	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.. 2021 , 12,	9
22	Bile salt hydrolase profiling by fluorogenic probes in the human gut microbiome.. 2022 , 664, 243-265	0
21	The emerging role of bile acids as critical components in nanotechnology and bioengineering: Pharmacology, formulation optimizers and hydrogel-biomaterial applications.. 2022 , 283, 121459	1
20	Effects of Diminished NADPH:cytochrome P450 Reductase in Human Hepatocytes on Lipid and Bile Acid Homeostasis. 2021 , 12, 769703	0
19	Activation of TGR5 Ameliorates Streptozotocin-Induced Cognitive Impairment by Modulating Apoptosis, Neurogenesis, and Neuronal Firing.. 2022 , 2022, 3716609	1
18	Tauroursodeoxycholic Acid Reduces Neuroinflammation but Does Not Support Long Term Functional Recovery of Rats with Spinal Cord Injury. 2022 , 10, 1501	0
17	Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in chronic liver disease rats and humans.	
16	Versatile Triad Alliance: Bile Acid, Taurine and Microbiota. 2022 , 11, 2337	0
15	Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era. 2022 , 14,	0
14	Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation. 2022 , 21,	
13	Dietary astaxanthin-rich extract ameliorates atherosclerosis/retinopathy and restructures gut microbiome in apolipoprotein E-deficient mice fed on a high-fat diet.	1
12	The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?. 2022 , 27, 5292	0
11	Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans. 11,	0
10	Eggerthella lenta DSM 2243 Alleviates Bile Acid Stress Response in Clostridium ramosum and Anaerostipes caccae by Transformation of Bile Acids. 2022 , 10, 2025	0
9	Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome. 2022 , 11, 1622	0
8	The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity. 2022 , 23, 13967	1

- 7 The role of bile acids and intestinal microbiota in metabolic transformations after gastric bypass surgery. **2022**, 25, 499-503 0
- 6 Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. **2022**, 14, 4950 1
- 5 Identification of the Role of TGR5 in the Regulation of Leydig Cell Homeostasis. **2022**, 23, 15398 0
- 4 Is TGR5 a therapeutic target for the treatment of spinal cord injury?. 0
- 3 The Black Box Orchestra of Gut Bacteria and Bile Acids: Who Is the Conductor?. **2023**, 24, 1816 1
- 2 Secondary bile acids and the biliary epithelia: The good and the bad. 29, 357-366 0
- 1 Sugarcane leaves-derived polyphenols alleviate metabolic syndrome and modulate gut microbiota of ob/ob mice. **2023**, 1-24 0